A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder

European Psychiatry

Volumn 22, Issue 7, 2007, Pages 444-447

  Papakostas, George I ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

5HT2; Depression; Nefazodone; SSRI; Trazodone

Indexed keywords

FLUOXETINE; NEFAZODONE; PAROXETINE; SEROTONIN 2 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

DEPRESSIVE DISORDER, MAJOR; HUMANS; RECEPTORS, SEROTONIN, 5-HT2; SEROTONIN UPTAKE INHIBITORS; TRAZODONE; TRIAZOLES;

EID: 35348944082     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2007.01.1220     Document Type: Article

References (34)

1. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58 1 (2000) 19-36
2. Armitage R., Yonkers K., Cole D., and Rush A.J. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol 17 3 (1997) 161-168
3. Avila A., Cardona X., Martin-Baranera M., Maho P., Sastre F., and Bello J. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol 23 5 (2003) 509-513
4. Baldwin D.S., Hawley C.J., Abed R.T., Maragakis B.P., Cox J., Buckingham S.A., et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 57 s(2) (1996) 46-52
5. Beasley Jr. C.M., Dornseif B.E., Pultz J.A., Bosomworth J.C., and Sayler M.E. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 52 7 (1991) 294-299
6. Berlanga C., Arechevaleta B., and Heinze G. A double-blind comparison of nefazodone and fluoxetine in the treatment of depressed outpatients. Salud Mental 20 (1997) 1-8
7. Debus J.R., Rush A.J., Himmel C., Tyler D., Polatin P., and Weissenburger J. Fluoxetine versus trazodone in the treatment of outpatients with major depression. J Clin Psychiatry 49 11 (1988) 422-426
8. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
9. Falk W.E., Rosenbaum J.F., Otto M.W., Zusky P.M., Weilburg J.B., and Nixon R.A. Fluoxetine versus trazodone in depressed geriatric patients. J Geriatr Psychiatry Neurol 2 4 (1989) 208-214
10. Feiger A., Kiev A., Shrivastava R.K., Wisselink P.G., and Wilcox C.S. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 57 s(2) (1996) 53-62
11. Ferguson J.M., Shrivastava R.K., Stahl S.M., Hartford J.T., Borian F., Ieni J., et al. Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. J Clin Psychiatry 62 1 (2001) 24-29
12. Fudge J.L., Perry P.J., Garvey M.J., and Kelly M.W. A comparison of the effect of fluoxetine and trazodone on the cognitive functioning of depressed outpatients. J Affect Disord 18 4 (1990) 275-280
13. Gillin J.C., Rapaport M., Erman M.K., Winokur A., and Albala B.J. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 58 5 (1997) 185-192
14. In: Guy W. (Ed). ECDEU Assessment manual for psychopharmacology, revised (1976), National Institute of Mental Health, Rockville, MD DHEW Pub. No. (ADM) 76-338
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
16. Hicks J.A., Argyropoulos S.V., Rich A.S., Nash J.R., Bell C.J., Edwards C., et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 180 (2002) 528-535
17. Kasper S., and Olie J.P. A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur Psychiatry 17 Suppl. 3 (2002) 331-340
18. Kasper S., Olivieri L., Di Loreto G., and Dionisio P. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin 21 8 (2005) 1139-1146
19. Laird N.M., and Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 6 (1990) 5-30
20. Montgomery S.A., and Asberg A. A new depression scale designed to be sensitive to change. Br J Psychiatry 134 (1979) 382-389
21. Mosteller F., and Colditz G.A. Understanding research synthesis (meta-analysis). Annu Rev Public Health 17 (1996) 1-23
22. Munizza C., Olivieri L., Di Loreto G., and Dionisio P. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 22 9 (2006) 1703-1713
23. Nelson J.C. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry 46 9 (1999) 1301-1308
24. Papakostas G.I., and Fava M. Monoamine-based pharmacotherapy. In: Licinio J. (Ed). Biology of depression: from novel insights to therapeutic strategies. 1st ed. (2005), Wiley-VCH, Weinheim 87-140
25. Papakostas G.I. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 16 6 (2006) 391-402
26. Papakostas G.I., and Fava M. Does the probability of receiving placebo influence the likelihood of responding to placebo or clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Neuropsychopharmacology 31 s1 (2006) s158
27. Papakostas G.I. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 16 6 (2006) 391-402
28. Papakostas G.I., and Fava M. A meta-analysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Can J Psychiatry 51 12 (2006) 783-790
29. Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. J Psychopharmacol, in press.
30. Perry P.J., Garvey M.J., Kelly M.W., Cook B.L., Dunner F.J., and Winokur G. A comparative trial of fluoxetine versus trazodone in outpatients with major depression. J Clin Psychiatry 50 8 (1989) 290-294
31. Petersen T., Papakostas G.I., Posternak M.A., Kant A., Guyker W.M., Iosifescu D.V., et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 25 4 (2005) 336-341
32. Rush A.J., Armitage R., Gillin J.C., Yonkers K.A., Winokur A., Moldofsky H., et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 44 1 (1998) 3-14
33. Sterne J.A., Gavaghan D., and Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53 11 (2000) 1119-1129
34. Thase ME, Lu Y, Joliat MJ, Detke MJ. Remission in placebo-controlled trials of duloxetine with an SSRI comparator. American Psychiatric Association Annual Meeting; 2003.